Betterlife Pharma Inc Financials
This page shows Betterlife Pharma Inc (BETRF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2018 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Betterlife Pharma Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Betterlife Pharma Inc carries a low D/E ratio of 0.92, meaning only $0.92 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 83/100, indicating a strong balance sheet with room for future borrowing.
Betterlife Pharma Inc generates a -2.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 5/100.
Betterlife Pharma Inc passes 0 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Betterlife Pharma Inc generates $3.26 in operating cash flow (-$396K OCF vs -$121K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Betterlife Pharma Inc earns $-38.3 in operating income for every $1 of interest expense (-$1.0M vs $27K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Betterlife Pharma Inc reported -$121K in net income in fiscal year 2018.
Cash & Balance Sheet
Betterlife Pharma Inc held $1.5M in cash against $0 in long-term debt as of fiscal year 2018.
Betterlife Pharma Inc had 88M shares outstanding in fiscal year 2018. This represents an increase of 16.4% from the prior year.
Margins & Returns
Betterlife Pharma Inc's ROE was -2.6% in fiscal year 2018, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Betterlife Pharma Inc invested $70K in research and development in fiscal year 2018.
BETRF Income Statement
| Metric | Q3'19 | Q2'19 | Q1'19 | Q4'18 | Q3'18 | Q2'18 | Q1'18 | Q4'17 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $65K-25.1% | $87K+1.7% | $85K | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $432K+1.0% | $428K-42.9% | $749K | N/A | $50K-33.3% | $76K+41.9% | $53K | N/A |
| Operating Income | -$1.4M-19.5% | -$1.2M+18.3% | -$1.4M | N/A | -$185K | N/A | -$286K | N/A |
| Interest Expense | $135K+39.1% | $97K+43.3% | $68K | N/A | $7K-12.4% | $8K-4.8% | $9K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.4M-138.8% | -$1.4M+12.9% | -$1.6M | N/A | $531K+9652.3% | -$6K+98.3% | -$320K | N/A |
| EPS (Diluted) | $-0.04 | N/A | N/A | N/A | $0.01 | N/A | N/A | N/A |
BETRF Balance Sheet
| Metric | Q3'19 | Q2'19 | Q1'19 | Q4'18 | Q3'18 | Q2'18 | Q1'18 | Q4'17 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.1M-6.7% | $7.6M-13.9% | $8.8M+2196.5% | $384K-28.3% | $535K+1385.0% | $36K-45.7% | $66K-49.9% | $133K |
| Current Assets | $556K-17.9% | $677K-59.2% | $1.7M+1012.0% | $149K-49.6% | $296K+793.0% | $33K-47.8% | $64K-51.1% | $130K |
| Cash & Equivalents | $407K-14.2% | $474K-68.6% | $1.5M+2242.0% | $65K-74.2% | $250K+2418.2% | $10K-78.7% | $47K-58.5% | $112K |
| Inventory | $7K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.7M-14.8% | $4.3M+1.5% | $4.2M+883.6% | $429K+21.9% | $352K-73.3% | $1.3M-26.6% | $1.8M+12.0% | $1.6M |
| Current Liabilities | $3.7M | N/A | N/A | $429K+186.1% | $150K-88.6% | $1.3M-26.6% | $1.8M+12.0% | $1.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.4M+3.9% | $3.3M-28.1% | $4.6M+10220.7% | -$45K-124.8% | $183K+114.2% | -$1.3M+25.9% | -$1.7M-17.5% | -$1.5M |
| Retained Earnings | -$27.1M-14.2% | -$23.8M-6.3% | -$22.3M-7.8% | -$20.7M-1.6% | -$20.4M+2.5% | -$20.9M0.0% | -$20.9M-1.6% | -$20.6M |
BETRF Cash Flow Statement
| Metric | Q3'19 | Q2'19 | Q1'19 | Q4'18 | Q3'18 | Q2'18 | Q1'18 | Q4'17 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$706K+28.2% | -$983K+47.5% | -$1.9M-855.5% | -$196K-103.7% | -$96K-149.6% | -$39K+40.7% | -$65K+34.8% | -$100K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$327K | $0+100.0% | -$333K | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $998K+1277.7% | -$85K-102.3% | $3.7M+13064.2% | $28K-90.9% | $307K+1265.0% | $23K+650.0% | $3K+283.8% | -$2K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BETRF Financial Ratios
| Metric | Q3'19 | Q2'19 | Q1'19 | Q4'18 | Q3'18 | Q2'18 | Q1'18 | Q4'17 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -98.5%-55.6pp | -42.9%-7.5pp | -35.4% | N/A | 290.1% | N/A | N/A | N/A |
| Return on Assets | -47.7%-29.1pp | -18.6%-0.2pp | -18.4% | N/A | 99.2%+114.6pp | -15.4%+466.2pp | -481.6% | N/A |
| Current Ratio | 0.15 | N/A | N/A | 0.35-1.6 | 1.97+1.9 | 0.03-0.0 | 0.04-0.0 | 0.08 |
| Debt-to-Equity | 1.06-0.2 | 1.30+0.4 | 0.92+10.4 | -9.46-11.4 | 1.93+3.0 | -1.03+0.0 | -1.04+0.1 | -1.09 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Betterlife Pharma Inc profitable?
No, Betterlife Pharma Inc (BETRF) reported a net income of -$121K in fiscal year 2018.
What is Betterlife Pharma Inc's return on equity (ROE)?
Betterlife Pharma Inc (BETRF) has a return on equity of -2.6% for fiscal year 2018, measuring how efficiently the company generates profit from shareholder equity.
What is Betterlife Pharma Inc's operating cash flow?
Betterlife Pharma Inc (BETRF) generated -$396K in operating cash flow during fiscal year 2018, representing cash generated from core business activities.
What are Betterlife Pharma Inc's total assets?
Betterlife Pharma Inc (BETRF) had $8.8M in total assets as of fiscal year 2018, including both current and long-term assets.
How much does Betterlife Pharma Inc spend on research and development?
Betterlife Pharma Inc (BETRF) invested $70K in research and development during fiscal year 2018.
What is Betterlife Pharma Inc's debt-to-equity ratio?
Betterlife Pharma Inc (BETRF) had a debt-to-equity ratio of 0.92 as of fiscal year 2018, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Betterlife Pharma Inc's return on assets (ROA)?
Betterlife Pharma Inc (BETRF) had a return on assets of -1.4% for fiscal year 2018, measuring how efficiently the company uses its assets to generate profit.
What is Betterlife Pharma Inc's cash runway?
Based on fiscal year 2018 data, Betterlife Pharma Inc (BETRF) had $1.5M in cash against an annual operating cash burn of $396K. This gives an estimated cash runway of approximately 46 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Betterlife Pharma Inc's Piotroski F-Score?
Betterlife Pharma Inc (BETRF) has a Piotroski F-Score of 0 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Betterlife Pharma Inc's earnings high quality?
Betterlife Pharma Inc (BETRF) has an earnings quality ratio of 3.26x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Betterlife Pharma Inc cover its interest payments?
Betterlife Pharma Inc (BETRF) has an interest coverage ratio of -38.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Betterlife Pharma Inc?
Betterlife Pharma Inc (BETRF) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.